$EP

EMPIRE PETROLEUM REPORTS FINANCIAL RESULTS FOR SECOND QUARTER 2026 AND PROVIDES OPERATIONAL UPDATE

EMPIRE PETROLEUM CORP (EP) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99 EMPIRE PETROLEUM REPORTS FINANCIAL RESULTS FOR SECOND QUARTER 2026 AND PROVIDES OPERATIONAL UPDATE TULSA, OK – (AUGUST 17, 2026) – Empire Petroleum Corporation (NYSE American: EP) ("Empire" or the "Company"), an oil and gas company with current producing assets in New

Original reporting
Published Aug 17, 2026, 8:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 17, 2026, 8:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$EP
Neutral
medium confidence
Mentioned
$EP
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$EPNeutralMed
01

Why it matters

Key new items include Q2 production and financial results, progress on Texas gas compression and deeper well evaluation, a North Dakota thermal retrofit milestone, and an amended Louisiana program plus an ATM equity sales agreement authorized up to $7.5M.

02

Market read

Traders can update models for EP based on the newly reported Q2 production mix, revenue and loss figures, adjusted EBITDA improvement, and the financing overhang from an ATM authorization.

03

What to watch

The excerpt notes impairments drove lower DD&A in Q2 2026; traders may scrutinize whether underlying economics improved or whether accounting effects are doing the work.

Relevance 7/10Novelty 7/10Timing: filed after market close, available for next-session positioning

Background

Empire Petroleum filed an SEC Form 8-K with its Q2 2026 results and operational updates across Texas, North Dakota, and Louisiana.

Company-level read

Ticker impact

$EPNeutralMedium confidence
Context

Empire Petroleum reported Q2 2026 results, including 1,825 Boe/d production, a $11.1M revenue figure, and a $1.9M net loss.

Expected impact

Near-term trading likely hinges on whether investors focus more on improving adjusted EBITDA versus dilution risk from the ATM authorization.

Evidence & confidence

This is a primary SEC filing with multiple new figures (production, revenue, net loss, adjusted EBITDA) and a new financing framework (ATM up to $7.5M), but the excerpt does not include full guidance or a clear catalyst beyond execution updates.

Market effects

Microcap oil and gas names may see read-across from execution progress tied to gas compression and reduced stranded-gas risk.

Operational updates are concentrated in Texas, North Dakota, and Louisiana, which can influence local sentiment around gas deliverability and thermal recovery execution.

Limited global impact; story is company-specific with no macro policy or commodity shock described.

Counterpoint

Investors may discount the operational milestones if they do not translate into sustained cash flow, especially given the authorized (though not yet used) ATM issuance.

Key entities

  • Empire Petroleum Corporation

    NYSE American-listed oil and gas producer reporting Q2 2026 results and operational milestones in the 8-K.

  • Roth Capital Partners

    Counterparty to the company’s at-the-market sales agreement referenced in the filing.

  • Starbuck Drilling Program

    North Dakota thermal recovery program where Empire completed a major retrofit milestone.

Related articles

$EPMed

Foot Well in the Western Haynesville in Texas to Accelerate Revenue Development

Empire Petroleum (NYSE American: EP) said it successfully re-entered and evaluated the Wakefield-Harrison GU B #1 well in Fort Trinidad, Texas, reaching 21,006 feet measured depth (20,949 feet TVD). The company reported modern open-hole logs and sidewall cores, with gas and liquids shows, and said the work cost about $4.4 million. The well is not completed or production tested.

$JNJMedAI 8/10

Johnson & Johnson Drops 5% as One-Time Charges Overshadow Raised Full-Year Outlook; Eli Lilly Dips, Pfizer Sits Out the Selloff

Johnson & Johnson (JNJ) stock fell 5% despite raising its full-year outlook due to one-time charges, including talc litigation. Q3 2026 revenue grew 5.9%, but reported net earnings dropped 95.9%. Eli Lilly (LLY) and Pfizer (PFE) also saw declines. JNJ's growth came from its Innovative Medicine division, while MedTech lagged. The company secured market authorization for its OTTAVA robotic surgical system and priority review for RYBREVANT FASPRO.

$JNJHighAI 8/10

Tremfya rescues J&J’s immunology sales to fuel strong Q3

Johnson & Johnson reported Q3 sales of $25.4bn, beating estimates. Tremfya's sales surged 68.3% to $2.4bn, driving a 7.9% increase in the pharma segment. Overall immunology sales grew 1.3%, offset by declines in Stelara, Remicade, and Simponi. J&J raised its 2026 sales and EPS guidance, despite lower Q3 EPS due to acquisitions and legal settlements. Medtech sales grew 2.5%, led by Shockwave's 16.8% increase.

$GSMedAI 8/10

Goldman Sachs Exceeds Q3 Expectations with Strong Revenue Growth

Goldman Sachs reported Q3 EPS of $17.01, beating estimates of $12.86. Revenue rose 23% YoY to $18.68B. Investment banking fees increased 21% to $3.22B, while equities revenue surged 72% to $6.44B. Operating expenses rose 20% to $11.31B, with a $450M charitable contribution reducing EPS by $1.00. CEO David Solomon noted macroeconomic challenges but highlighted U.S. economic resilience and opportunities in M&A and AI infrastructure.